Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
Por:
Peyrin-Biroulet, L, Sandborn, WJ, Panaccione, R, Domenech, E, Pouillon, L, Siegmund, B, Danese, S and Ghosh, S
Publicada:
1 dic 2021
Ahead of Print:
9 dic 2021
Resumen:
In the 1990s, tumour necrosis factor-alpha inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-alpha inhibitors approved as treatments for ulcerative colitis and/or Crohn's disease: infliximab, adalimumab, golimumab and certolizumab pegol. Despite the clear benefits of tumour necrosis factor-alpha inhibitors, a subset of patients with inflammatory bowel disease either do not respond, experience a loss of response after initial clinical improvement or report intolerance to anti-tumour necrosis factor-alpha therapy. Optimizing outcomes of these agents may be achieved through earlier intervention, the use of therapeutic drug monitoring and thoughtful switching within class. To complement these approaches, evolving predictive biomarkers may help inform and optimize clinical decision making by identifying patients who might potentially benefit from an alternative treatment strategy. This review will focus on the current use of tumour necrosis factor-alpha inhibitors in inflammatory bowel disease and the application of personalized medicine to improve future outcomes for all patients.
Filiaciones:
Peyrin-Biroulet, L:
Univ Lorraine, Dept Gastroenterol, Univ Hosp Nancy, Vandoeuvre Les Nancy, France
Univ Lorraine, Inserm NGERE U1256, Univ Hosp Nancy, Vandoeuvre Les Nancy, France
Sandborn, WJ:
Univ Calif San Diego, La Jolla, CA 92093 USA
Panaccione, R:
Univ Calgary, Cumming Sch Med, Calgary, AB, Canada
Univ Calgary, Inflammatory Bowel Dis Unit, Calgary, AB, Canada
:
Hosp Badalona Germans Trias & Pujol, Badalona, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
Pouillon, L:
Imeldaziekenhuis Bonheiden, Imelda GI Clin Res Ctr, Bonheiden, Belgium
Siegmund, B:
Charite Univ Med Berlin, Med Klin Gastroenterol Infektiol & Rheumatol, Berlin, Germany
Free Univ Berlin, Berlin, Germany
Humboldt Univ, Berlin, Germany
Berlin Inst Hlth, Berlin, Germany
Danese, S:
IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
Univ Vita Salute San Raffaele, Milan, Italy
Ghosh, S:
Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England
Univ Birmingham, NIHR Biomed Res Ctr, Birmingham B15 2TH, W Midlands, England
Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
gold, Green Published
|